---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-045250"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:42:23.595169+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elanco spins out microbiome platform into BiomEdit with $40M funding; tenders $406M of 2023 notes

## Summary
- Elanco launches BiomEdit, a microbiome innovation company, with $40M Series A from Viking Global and Anterra Capital.
- Elanco contributes IP and pipeline to BiomEdit; retains non-voting equity; combined Elanco/Ginkgo ownership ~40% fully diluted.
- Tender offer: $406M (54.19%) of 4.272% notes due 2023 tendered; cap raised to $406M; early acceptance at $1,035 per $1,000.
- BiomEdit to leverage Ginkgo's cell programming platform for probiotics, bioactives, and engineered microbial medicines.
- Aaron Schacht named CEO of BiomEdit; enters consulting agreement with Elanco at $250/hour for advisory role.

## SEC filing metadata
- accession: 0001104659-22-045250
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465922045250/0001104659-22-045250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465922045250/tm2212574d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-045250
- JSON: https://secwatch.observer/filing/0001104659-22-045250.json
- Plain text: https://secwatch.observer/filing/0001104659-22-045250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.